AUTHORS
Andrew McPherson, PhD, Sarun Sereewattanawoot, MD, PhD2, Matthew Myers, PhD3, Eliyahu Havasov4, Huiyoung Yun, PhD5, Kylee Maclachlan, MD, PhD6, Neha Korde, MD7, Gareth Morgan, MD, PhD8, Nizar Bahlis, MD9, Ross Firestone, MD/PhD10, Marta Chesi, PhD11, Mariano Arribas12, Gregory Ahmann, BS13, J Erin Wiedmeier-Nutor, MD,MPH14, Rafael Fonseca, MD15, P. Leif Bergsagel, MD16, Saad Z. Usmani, MD17, Sohrab Shah, PhD18, Francesco Maura, MD19
AFFILIATIONS
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 Memorial Sloan Kettering Cancer Center, New York, New York, United States
3 Memorial Sloan Kettering Cancer Center, New York, New York, United States
4 Memorial Sloan Kettering Cancer Center, New York, New York, United States
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 Perlmutter Cancer Center, NYU Langone Health, New York, New York, United States
9 University of Calgary, Calgary, Alberta, Canada
10 Memorial Sloan Kettering Cancer Center, New York, New York, United States
11 Mayo Clinic, Phoenix, Arizona, United States
12 Mayo Clinic, Phoenix, Arizona, United States
13 Mayo Clinic, Phoenix, Arizona, United States
14 Mayo Clinic, Phoenix, Arizona, United States
15 Mayo Clinic, Phoenix, Arizona, United States
16 Mayo Clinic, Phoenix, Arizona, United States
17 Memorial Sloan Kettering Cancer Center, New York, New York, United States
18 Memorial Sloan Kettering Cancer Center, New York, New York, United States
19 Memorial Sloan Kettering Cancer Center, New York, New York, United States
ABSTRACT
BACKGROUND: Multiple myeloma (MM) is driven by the accumulation of genomic alterations over decades. Bulk whole-genome sequencing (WGS) has defined canonical initiating events and temporal patterns of tumor evolution, but its limited resolution prevents confident detection of subclonal events below 10–20% cancer cell fraction, leaving critical aspects of MM clonal dynamics unresolved.
METHODS: We applied single-cell whole-genome sequencing using the DLP+ platform (McPherson, Nature 2025) to CD138+ plasma cells from 22 patients spanning the disease spectrum [1 MGUS, 6 smoldering MM (SMM), 13 newly diagnosed MM (NDMM), 2 relapsed MM (RRMM)]. In contrast to other single-cell platforms, DLP+ enables the detection of single nucleotide variants (SNVs), indels, structural variants (SVs), and allele-specific copy number alterations (CNAs) at the single-cell level, and leveraging this information, we reconstructed single-cell phylogenetic trees and quantified ongoing genomic instability. Findings were validated in an external independent dataset of 65 NDMM sequenced using the 10X Chromium Single Cell CNA kit.
RESULTS: Phylogenetic reconstruction revealed two distinct evolutionary architectures. In 8 NDMM patients, most mutations resided in the truncal branch (most recent common ancestor, MRCA), consistent with a typical Darwinian model in which one clone is selected over time and subsequently undergoes late clonal diversification. In contrast, 5 NDMM patients displayed evidence of "early divergent evolution," in which two or more large subclones carrying distinct copy number profiles branched early from the MRCA and subsequently evolved, coexisting until diagnosis. In this model, most mutations reside in the branches and relatively few in the MRCA, indicating that genetically divergent clones had independently expanded in the bone marrow for years before clinical presentation. In all patients, the germinal center–associated signature SBS9 was significantly enriched in the MRCA (p<0.001), confirming a shared post-germinal center origin even in patients with “early divergent evolution”. In contrast, APOBEC mutagenesis—traditionally considered a late event—was detected in early branches immediately after divergence from the MRCA, suggesting it initiates shortly after malignant transformation. Evidence of “early divergent evolution” was also present in precursor disease: longitudinal sampling of one t(4;14) SMM patient over 8 years showed a clone with del(13q), nearly undetectable at SMM diagnosis, ultimately achieving clonal dominance at MM progression and replacing a hyperdiploid clone that had been dominant for most of the follow-up period. The only case where different clones originated from distinct MRCAs was the MGUS case, in which at least three independent and unrelated plasma cell clones were detected by scWGS DLP+, a finding validated by clonoseq of their immunoglobulin sequences.
We next assessed patterns of acquisition of key aneuploidies, classifying all events into three groups: clonal (MRCA), subclonal (shared by a cluster of cells in the phylogenetic tree), and cell-specific. This analysis was enhanced by the ability of DLP+ to capture allele-specific CNAs, uncovering an unexpectedly complex landscape of competition and convergent evolution. Allele-specific analysis often revealed that gains seemingly acquired by all cells in a patient were in fact derived from two subclonal populations, one acquiring the paternal and one the maternal allele. These patterns of widespread convergent evolution were observed for 1q gain, 13q loss, and 16q loss/gain, with some patients showing up to 6–8 distinct allelic combinations of the same aneuploidies. Hyperdiploidy was clonal in 7 patients but subclonal in 3 patients and cell-specific in 2 patients, providing direct evidence that this canonical initiating event can arise late. We estimated that 1q gain and 16q loss are detectable in at least one cell in 77% and 82% of NDMM, respectively. Validation in 65 10X single-cell CNA profiles from NDMM samples confirmed widespread convergent evolution and the high prevalence of CNAs once subclonal and cell-specific events are accounted for, with 1q gain, and 16q loss found in 71% and 72% of the 10X samples, respectively.
CONCLUSION: scWGS DLP+ uncovers a previously hidden layer of myeloma clonal complexity, redefining the genomic life history of MM and providing a framework for understanding how early clonal competition shapes progression.
DISCLOSURES
Andrew McPherson, PhD: No relevant conflicts of interest to declare.